Comparison of the prognostic capability of two comorbidity indices in patients with chronic obstructive pulmonary disease, in real‐life clinical practice

Figueira‐Gonçalves, Juan Marco; Golpe, Rafael; García‐Bello, Miguel Ángel; García‐Talavera, Ignacio; Castro‐Añón, Olalla

doi:10.1111/crj.13025

Cited by 14 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1) for any comorbidity. The Charlson Comorbidity Index is a common scoring system for the prediction of mortality and prognosis in many diseases, including COPD (19). In our study, the correlation of neutrophilia with the Charlson Comorbidity Index was less signi cant than the correlations with the numbers of the 11 comorbidities.…”

Section: Discussioncontrasting

confidence: 49%

Suppressor of Variegation 3-9 Homologue 1 Impairment and Neutrophil-Skewed Systemic Inflammation Are Associated with Comorbidities in COPD

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND: Systemic manifestations and comorbidities are characteristics of chronic obstructive pulmonary disease (COPD) and are probably due to systemic inflammation. The histone methyltransferase SUV39H1 controls the Th1/Th2 balance. We previously reported that reduced SUV39H1 expression contributed to abnormal inflammation in COPD.METHODS: To assess whether impaired SUV39H1 expression in COPD patients leads to neutrophilic inflammation, downstream responses to IL-8 and suppression of Th2 responses, the SUV39H1 levels in peripheral blood mononuclear cells (PBMCs) from 10 healthy subjects and 14 COPD patients were measured by immunoblotting. Clinical outcomes associated with SUV39H1-related inflammation were also studied. The relationships between SUV39H1 and neutrophil or eosinophil (Th2 response) counts and clinical outcomes were evaluated. In an extended COPD cohort (213 patients), association analyses of blood cell counts with comorbidities and exacerbations were performed.RESULTS: Low SUV39H1 expression was associated with high neutrophil counts and a trend towards low eosinophil counts. In the extended cohort, the high comorbidity group had higher neutrophil counts than the low comorbidity group but similar whole white blood cell counts. The eosinophil percentage and eosinophil/neutrophil ratio displayed contrasting results. The proportion of neutrophils was correlated with COPD comorbidities. Patients with 0-1 moderate to severe exacerbations in the past year had numbers of neutrophils and eosinophils similar to those of patients who experienced more than an exacerbation. Finally, patients with high comorbidities had lower SUV39H1 levels in their PBMCs than did those with low comorbidities.CONCLUSION: Blood neutrophil counts are associated with comorbidities in COPD patients. Impaired SUV39H1 expression in PBMCs from COPD patients are correlated with neutrophilic inflammation and comorbidities.

show abstract

Section: Discussioncontrasting

confidence: 49%

Suppressor of Variegation 3-9 Homologue 1 Impairment and Neutrophil-Skewed Systemic Inflammation Are Associated with Comorbidities in COPD

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…However, our results revealed no statistical signi cance for any single comorbidity correlated with neutrophilia. The Charlson Comorbidity Index is a common scoring system for the prediction of mortality and prognosis in many diseases, including COPD (19). In our study, the correlation of neutrophilia with the Charlson Comorbidity Index was less signi cant than the correlations with the numbers of the 11 comorbidities.…”

Section: Discussioncontrasting

confidence: 49%

Suppressor of Variegation 3-9 Homologue 1 Impairment and Neutrophil-skewed Systemic Inflammation Are Associated with Comorbidities in COPD

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND: Systemic manifestations and comorbidities are characteristics of chronic obstructive pulmonary disease (COPD) and are probably due to systemic inflammation. The histone methyltransferase SUV39H1 controls the Th1/Th2 balance. We previously reported that reduced SUV39H1 expression contributed to abnormal inflammation in COPD.METHODS: To assess whether impaired SUV39H1 expression in COPD patients leads to neutrophilic inflammation, downstream responses to IL-8 and suppression of Th2 responses, the SUV39H1 levels in peripheral blood mononuclear cells (PBMCs) from 13 healthy subjects and 30 COPD patients were measured by immunoblotting. Clinical outcomes associated with SUV39H1-related inflammation were also studied. The relationships between SUV39H1 and neutrophil or eosinophil (Th2 response) counts and clinical outcomes were evaluated. In an extended COPD cohort (213 patients), association analyses of blood cell counts with comorbidities and exacerbations were performed.RESULTS: Low SUV39H1 expression was associated with high neutrophil counts and a trend towards low eosinophil counts. In the extended cohort, the high comorbidity group had higher neutrophil counts than the low comorbidity group but similar whole white blood cell counts. The eosinophil percentage and eosinophil/neutrophil ratio displayed contrasting results. The proportion of neutrophils was correlated with COPD comorbidities. Patients with 0-1 moderate to severe exacerbations in the past year had numbers of neutrophils and eosinophils similar to those of patients who experienced more than an exacerbation. Finally, patients with high comorbidities had lower SUV39H1 levels in their PBMCs than did those with low comorbidities.CONCLUSION: Blood neutrophil counts are associated with comorbidities in COPD patients. Impaired SUV39H1 expression in PBMCs from COPD patients are correlated with neutrophilic inflammation and comorbidities.

show abstract

“…Although the CCI is a validated tool that predicts 1-year mortality in older adults [15], it has never been specifically validated in patients with ILD. We chose to include the CCI in CARE-PF given the lack of an alternative validated comorbidity index for ILD at the time of study design, it’s extensive use and validation in other chronic diseases [26–28] and validated use in health services research [29–31]. However, the CCI had a very narrow distribution across our cohort of fibrotic ILD, suggesting it may be a poor discriminator in assessing the impact of comorbidities on patients with ILD.…”

Section: Discussionmentioning

confidence: 99%

Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis

et al. 2019

View full text Add to dashboard Cite

BackgroundThe CAnadian REgistry for Pulmonary Fibrosis (CARE-PF) is a multi-center, prospective registry designed to study the natural history of fibrotic interstitial lung disease (ILD) in adults. The aim of this cross-sectional sub-study was to describe the baseline characteristics, risk factors, and comorbidities of patients enrolled in CARE-PF to date.MethodsPatients completed study questionnaires and clinical measurements at enrollment and each follow-up visit. Environmental exposures were assessed by patient self-report and comorbidities by the Charlson Comorbidity Index (CCI). Baseline characteristics, exposures, and comorbidities were described for the overall study population and for incident cases, and were compared across ILD subtypes.ResultsThe full cohort included 1285 patients with ILD (961 incident cases (74.8%)). Diagnoses included connective tissue disease-associated ILD (33.3%), idiopathic pulmonary fibrosis (IPF) (24.7%), unclassifiable ILD (22.3%), chronic hypersensitivity pneumonitis (HP) (7.5%), sarcoidosis (3.2%), non-IPF idiopathic interstitial pneumonias (3.0%, including idiopathic nonspecific interstitial pneumonia (NSIP) in 0.9%), and other ILDs (6.0%). Patient-reported exposures were most frequent amongst chronic HP, but common across all ILD subtypes. The CCI was ≤2 in 81% of patients, with a narrow distribution and range of values.ConclusionsCTD-ILD, IPF, and unclassifiable ILD made up 80% of ILD diagnoses at ILD referral centers in Canada, while idiopathic NSIP was rare when adhering to recommended diagnostic criteria. CCI had a very narrow distribution across our cohort suggesting it may be a poor discriminator in assessing the impact of comorbidities on patients with ILD.

show abstract

Comparison of the prognostic capability of two comorbidity indices in patients with chronic obstructive pulmonary disease, in real‐life clinical practice

Cited by 14 publications

References 11 publications

Suppressor of Variegation 3-9 Homologue 1 Impairment and Neutrophil-Skewed Systemic Inflammation Are Associated with Comorbidities in COPD

Suppressor of Variegation 3-9 Homologue 1 Impairment and Neutrophil-Skewed Systemic Inflammation Are Associated with Comorbidities in COPD

Suppressor of Variegation 3-9 Homologue 1 Impairment and Neutrophil-skewed Systemic Inflammation Are Associated with Comorbidities in COPD

Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis

Contact Info

Product

Resources

About